bioAffinity Stock (NASDAQ:BIAF)

Revenue Ownership Financials Chart

Previous Close

$0.67

52W Range

$0.61 - $13.50

50D Avg

$1.19

200D Avg

$1.77

Market Cap

$2.99M

Avg Vol (3M)

$422.01K

Beta

-1.11

Div Yield

-

BIAF Company Profile

As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.

Industry

Medical - Diagnostics & Research

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

57

IPO Date

Sep 01, 2022

Website

BIAF Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Dec 25	Dec 24	Dec 23
Other Revenues	$4.86K	$21.52K	-
Health Care, Patient Service	$4.97M	$516.00K	-
Health Care, Other	-	-	$19.32K

Fiscal year ends in Dec 24 | Currency in USD

BIAF Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	$9.36M	$2.53M	$4.80K
Operating Income	$9.44M	$-7.97M	$-4.01M
Net Income	$-9.04M	$-7.94M	$-8.15M
EBITDA	-	$-7.63M	$-5.61M
Basic EPS	-	$-0.91	$-1.81
Diluted EPS	-	$-0.91	$-1.81

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
PBM	Psyence Biomedical Ltd.
CARM	Carisma Therapeutics, Inc.
MNDR	Mobile-health Network Solutions Class A Ordinary Shares
WOK	WORK Medical Technology Group Ltd. Class A
ARTL	Artelo Biosciences, Inc.
GTBP	GT Biopharma, Inc.
REVB	Revelation Biosciences, Inc.
PTIX	Protagenic Therapeutics, Inc.